Shuttle Pharmaceuticals Holdings Inc (SHPH)
1.119
-0.03
(-2.69%)
USD |
NASDAQ |
Nov 13, 16:00
1.04
-0.08
(-7.07%)
After-Hours: 20:00
Shuttle Pharmaceuticals Holdings Research and Development Expense (Quarterly): 0.6457M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.6457M |
| March 31, 2024 | 0.5861M |
| December 31, 2023 | 0.4326M |
| September 30, 2023 | 1.140M |
| June 30, 2023 | 0.8397M |
| March 31, 2023 | 0.9218M |
| December 31, 2022 | -0.0014M |
| Date | Value |
|---|---|
| September 30, 2022 | 0.669M |
| June 30, 2022 | 0.0839M |
| March 31, 2022 | 0.2959M |
| December 31, 2021 | 0.4421M |
| September 30, 2021 | 0.187M |
| June 30, 2021 | 0.2867M |
| March 31, 2021 | 0.106M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-0.0014M
Minimum
Dec 2022
1.140M
Maximum
Sep 2023
0.474M
Average
0.4374M
Median
Research and Development Expense (Quarterly) Benchmarks
| Oragenics Inc | 0.9068M |
| Lixte Biotechnology Holdings Inc | 0.2107M |
| Soligenix Inc | 0.533M |
| Tonix Pharmaceuticals Holding Corp | 9.698M |
| NovaBay Pharmaceuticals Inc | 0.009M |